Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kala

- PMLiVE

New court filing alleges Sanofi destroyed emails relating to Zantac recall

Drugmaker began recalling heartburn drug in 2019 after link to probable human carcinogen

- PMLiVE

AZ, Sanofi’s nirsevimab hits primary endpoint in RSV trial

Drug reduced lower respiratory tract infections caused by respiratory syncytial virus in infants

Lucid Group is building its data analytics capability

Lucid Group is building a new data analytics capability into its teams with the appointment of Darren Selmes as its new analyst. This appointment signals the start of a stronger...

Lucid Group Communications Limited

- PMLiVE

Lucid Group promotes Clare Reynolds to Director of Business Development and Commercial Integration

As Lucid continues to evolve, its people have remained at the heart of its success. Clare Reynolds has played a key part in Lucid’s journey for nearly 12 years, during...

Lucid Group Communications Limited

- PMLiVE

Second Sarclisa combination regimen for multiple myeloma approved in EU

Second indication for Sarclisa covers drug’s use in combination with another standard myeloma treatment

- PMLiVE

Sanofi pays $160m upfront to acquire Tidal Therapeutics

French pharma company's acquisition of pre-clinical stage biotech includes mRNA-based research platform

Lucid Group Bolster its Senior Leadership Team

Lucid Group are delighted to welcome Jo Troman to the role of Managing Partner for team Origins. Jo has a wealth of industry experience from both client and agency sides....

Lucid Group Communications Limited

- PMLiVE

A Stellar Start to 2021 for Lucid Group

It’s been a stellar start to 2021 for Lucid Group, which has welcomed 38 new starters into the company since the beginning of the year. These include 15 Client Services...

Lucid Group Communications Limited

- PMLiVE

Sanofi and Translate Bio launch phase 1/2 trial of mRNA-based COVID-19 vaccine

Vaccine candidate induced high antibody levels in preclinical studies

- PMLiVE

Sanofi, Regeneron’s Libtayo shows marked reduction in risk of death in cervical cancer patients

Phase 3 trial showed drug reduced the risk of death by 31% compared to chemotherapy

- PMLiVE

Healthcare agency Page & Page and Partners welcomes wave of new talent

Page & Page and Partners has welcomed six new joiners across its Creative and Client Services teams.

Page & Page and Partners

- PMLiVE

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

New approval will see Libtayo compete with blockbuster immunotherapy Keytruda

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links